These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 15837614)

  • 1. Second-generation vaccines against leishmaniasis.
    Coler RN; Reed SG
    Trends Parasitol; 2005 May; 21(5):244-9. PubMed ID: 15837614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a leishmaniasis vaccine: the importance of MPL.
    Reed SG; Coler RN; Campos-Neto A
    Expert Rev Vaccines; 2003 Apr; 2(2):239-52. PubMed ID: 12899575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines in leishmaniasis: advances in the last five years.
    Brodskyn C; de Oliveira CI; Barral A; Barral-Netto M
    Expert Rev Vaccines; 2003 Oct; 2(5):705-17. PubMed ID: 14711330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant DNA-derived leishmania proteins: from the laboratory to the field.
    Kubar J; Fragaki K
    Lancet Infect Dis; 2005 Feb; 5(2):107-14. PubMed ID: 15680780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis.
    Reis AB; Giunchetti RC; Carrillo E; Martins-Filho OA; Moreno J
    Trends Parasitol; 2010 Jul; 26(7):341-9. PubMed ID: 20488751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmania vaccines: progress and problems.
    Kedzierski L; Zhu Y; Handman E
    Parasitology; 2006; 133 Suppl():S87-112. PubMed ID: 17274851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Live attenuated Leishmania vaccines: a potential strategic alternative.
    Silvestre R; Cordeiro-da-Silva A; Ouaissi A
    Arch Immunol Ther Exp (Warsz); 2008; 56(2):123-6. PubMed ID: 18373245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leishmania donovani: identification of novel vaccine candidates using human reactive sera and cell lines.
    Arora SK; Pal NS; Mujtaba S
    Exp Parasitol; 2005 Mar; 109(3):163-70. PubMed ID: 15713447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress towards a Leishmania vaccine.
    Tabbara KS
    Saudi Med J; 2006 Jul; 27(7):942-50. PubMed ID: 16830009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
    Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
    Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenicity of a whole parasite vaccine as promising candidate against canine leishmaniasis.
    Giunchetti RC; Reis AB; da Silveira-Lemos D; Martins-Filho OA; Corrêa-Oliveira R; Bethony J; Vale AM; da Silva Quetz J; Bueno LL; França-Silva JC; Nascimento E; Mayrink W; Fujiwara RT
    Res Vet Sci; 2008 Aug; 85(1):106-12. PubMed ID: 17950391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis.
    Calvopina M; Barroso PA; Marco JD; Korenaga M; Cooper PJ; Nonaka S; Hashiguchi Y
    Vaccine; 2006 Jul; 24(27-28):5645-52. PubMed ID: 16621179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunology of Leishmania infection and the implications for vaccine development.
    Vanloubbeeck Y; Jones DE
    Ann N Y Acad Sci; 2004 Oct; 1026():267-72. PubMed ID: 15604504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA based vaccination with a cocktail of plasmids encoding immunodominant Leishmania (Leishmania) major antigens confers full protection in BALB/c mice.
    Ahmed SB; Touihri L; Chtourou Y; Dellagi K; Bahloul C
    Vaccine; 2009 Jan; 27(1):99-106. PubMed ID: 18951941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Future vaccines in parasitology].
    Lagardère B
    Bull Soc Pathol Exot; 1991; 84(5 Pt 5):926-34. PubMed ID: 1819438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccine candidates for leishmaniasis: a review.
    Nagill R; Kaur S
    Int Immunopharmacol; 2011 Oct; 11(10):1464-88. PubMed ID: 21616175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine development against Trypanosoma cruzi and Leishmania species in the post-genomic era.
    Dumonteil E
    Infect Genet Evol; 2009 Dec; 9(6):1075-82. PubMed ID: 19805015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of vaccines against leishmaniasis.
    Modabber F
    Scand J Infect Dis Suppl; 1990; 76():72-8. PubMed ID: 2102023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.
    Fujiwara RT; Vale AM; França da Silva JC; da Costa RT; Quetz Jda S; Martins Filho OA; Reis AB; Corrêa Oliveira R; Machado-Coelho GL; Bueno LL; Bethony JM; Frank G; Nascimento E; Genaro O; Mayrink W; Reed S; Campos-Neto A
    Vet Res; 2005; 36(5-6):827-38. PubMed ID: 16120256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccines for leishmaniasis in the fore coming 25 years.
    Palatnik-de-Sousa CB
    Vaccine; 2008 Mar; 26(14):1709-24. PubMed ID: 18295939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.